R&D channel feed – Endpoints News

R&D channel feed

What makes a PhII drug worth up to $665M? Researchers spell it out for Novartis

9 years ago

#ASH16: Pfizer offers a thumbs-up on OS data from PhII blood cancer study of glasdegib

9 years ago

In wake of a CAR-T restructuring, Novartis says it’s ready to hunt a pioneering OK for lead program

9 years ago

Lethally severe neurotoxicity continues to haunt Juno’s CAR-T pipeline

9 years ago

Booming CRISPR pioneer Intellia looks to double staff with new digs

9 years ago

Cutting back in the UK, Takeda spins out its top neuroscience team into a transatlantic biotech

9 years ago

Round 2 in Boehringer's US reorganization will claim another 244 jobs, including small molecule group

9 years ago

A disruptive billionaire with a yen for innovation herds top researchers into a neoantigen cancer coalition

9 years ago

Bluebird, Celgene jump off to a promising start in the marathon race to develop a CAR-T for multiple myeloma

9 years ago

In Lechleiter's final days, Eli Lilly flags upcoming job cuts in the wake of a PhIII implosion

9 years ago

Gut check: Newest microbiome startup concentrates on autism, Parkinson’s disease

9 years ago

Investigators prep PhIII in effort to move MDMA (you know it as ecstasy) off the street and into use for PTSD

9 years ago

Fresh enthusiasm for Cerecor sours as lead drug flops in PhII depression study, shares crater

9 years ago

Hot on the heels of a clinical hold, Arrowhead torches its clinical pipeline, slashes staff

9 years ago

Step aside AstraZeneca, Pfizer/Merck KGaA jump ahead, getting a speedy review for their checkpoint rival avelumab

9 years ago

AstraZeneca spins out a bispecific antibody into a new cancer biotech with partner AbPro

9 years ago

Nivalis shares in meltdown as cystic fibrosis promise withers in PhII flop

9 years ago

Amicus maps out a 3-year delay at the FDA for lead drug, sending shares into a tailspin

9 years ago

Tired of being dumped by pharma partners, Vanderbilt’s neuroscience team takes a bold aim at the clinic

9 years ago

Will J&J come up with a big enough treasure trove to win an Actelion buyout?

9 years ago

Two more patients die as Juno’s lead CAR-T turns lethal again; trial halted

9 years ago

GSK targets a new indication for Nucala, flags PhIII success for a rare disease

9 years ago

It’s over: Eli Lilly shares tank after its huge gamble on Alzheimer’s drug solanezumab ends in failure

9 years ago

Ex-Allergan prez Ingram forges $1B deal to sell Alzheimer’s biotech to Brent Saunders and the new crew at Allergan

9 years ago

First page Previous page 309 310 311312313 314 315 Next page Last page